New drug combo tested in aggressive blood cancer
NCT ID NCT07444710
Summary
This early-stage study aims to find a safe and effective dose of a new drug called glofitamab when given alongside standard chemotherapy for people with previously untreated mantle cell lymphoma, a type of blood cancer. The main goal is to check for side effects and determine the best dose for future research. About 16 adults with specific stages of the cancer will receive the drug combination over multiple treatment cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.